Active Biotech AB Interim report January - June 20

        Laquinimod

• The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
• The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
• Positive results concerning laquinimod were presented at the 68th AAN Annual Meeting (American Academy of Neurology), held in Vancouver, Canada, on April 15-21, 2016

Tasquinimod     

• The complete study results of the Phase 3 10TASQ10 study have been published in the Journal of Clinical Oncology
• Out-licensing activities are continuing

ANYARA, Paquinimod (57-57) and SILC (ISI)

• Out-licensing activities are continuing

Financial summary

• Refocusing of the company is completed, operating costs reduced by 71% (SEK 95.2 M) compared with 2015  
• The number of employees will be reduced from 56 (June 2015) to 17 by the end of the third quarter of 2016  
• Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:      

The report is also available at www.activebiotech.com .

HUG#2034058